A supplemental application for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) received FDA approval on October 27, 2025. This approval pertains to the efficacy of the drug, as indicated by the FDA's classification of the supplemental application.
Background
Nivolumab, marketed as Opdivo Qvantig when combined with hyaluronidase-nvhy, is a known therapeutic agent. This supplemental approval specifically addresses the efficacy of the drug formulation, indicating an expansion or modification related to its proven effectiveness.
What this means
The FDA's supplemental approval for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) on October 27, 2025, signifies that new data supporting the drug's efficacy has been reviewed and accepted. While the specific details of the expanded indication or population are not provided in the current information, this type of approval typically allows for a broader application of the drug or an update to its existing label based on new clinical evidence. Clinicians and patients can expect updated prescribing information reflecting this efficacy approval for nivolumab and hyaluronidase-nvhy.
Source
The information regarding this supplemental approval was obtained from the FDA. The approval of the supplemental application for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), identified as BLA 761381 S-1, was recorded on October 27, 2025, and is accessible via accessdata.fda.gov.